



# GLAND PHARMA LIMITED

December 03, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Change(s) in Senior Management Personnel (“SMP”)**

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that Mr. Ankit Gupta, Vice President (Strategy, Investments & Investor Relations) and SMP of the Company has tendered resignation to pursue other interests and opportunities.

The resignation was accepted and approved by the members of the Nomination and Remuneration Committee of the Board of Directors on December 03, 2024, and he would be relieved from his official duties from the close of business hours on December 31, 2024 and consequently he shall cease to be the SMP of the Company with effect from January 01, 2025.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** and a copy of his resignation letter as given in **Annexure-B** are enclosed herewith.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary & Compliance Officer**

**Encl:** Annexures A & B

**Annexure A**

**Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**Details of Mr. Ankit Gupta**

<b>Sl. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. Ankit Gupta would cease to be the Vice President (Strategy, Investments & Investor Relations) of the Company by virtue of his resignation.
2	Date of Change	31.12.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

November 10, 2024

**Mr. Srinivas Sadu**  
**Executive Chairman and CEO**  
**Gland Pharma Limited,**  
**Hyderabad**

Dear Mr. Sadu,

Please accept this letter as formal notification that I am resigning from my position as **Vice President and Head of Investments, Strategy, and Investor Relations of Gland Pharma Limited**, effective 31<sup>st</sup> December 2024.

This was not an easy decision, as I have truly enjoyed my time at Gland. I am grateful for the opportunities I have been given during my tenure in India and at Cenexi.

However, I have decided to pursue a new opportunity that offers growth and aligns more closely with my long-term professional goals.

I am committed to ensuring a smooth transition during my departure and am happy to assist in any way possible to facilitate the handover of my responsibilities.

Thank you again for the opportunity to work at Gland.

I wish you and the company all the best in the future.

Sincerely,

  
**Ankit Gupta**

*Accepted  
to be returned on 31/12/24.  
Ankit  
31/12/24*

